REDUCE stands for: Randomized Evaluation of short-term DUal anti platelet therapy in patients with acute coronary syndrome treated with the COMBO Dual Therapy StEnt
The trial is designed to evaluate the potential for shorter-term dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients treated with the COMBO Dual Therapy Stent. The physician-initiated, prospective, multicenter, randomized trial has now completed enrollment of all 1,500 patients in 36 centers in Asia and Europe.
The primary endpoint is the composite of all-cause mortality, any myocardial infarction (MI), Target Vessel Revascularization (TVR), stroke and major bleeding from enrollment to 12 months. Patients have been randomized in a 1:1 fashion to receive either three or 12 months of DAPT.
Principal investigators are Prof. Harry Suryapranata MD, PhD, Radboud University Medical Center, Nijmegen, The Netherlands; and Prof. Giuseppe de Luca MD, PhD, Novara Hospital, Novara, Italy. Elvin Kedhi MD, PhD, the executive director of the trial, performed the first implant at Isala Hospital in The Netherlands in June, 2014.
Clinical trial information:
Camaro C, Damen SA, Brouwer MA et al. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial. Am Heart J 2016;178:37-44.
Suryapranata H, De Luca G. REDUCE: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES with a Luminal CD34+Antibody Coating in Patients with ACS. Oral presentation at the 29th annual Transcatheter Cardiovascular Therapeutics scientific symposium, November 1, 2017.
TCT congress: www.tctmd.com/news/shortened-dapt-durations-appear-safe-patients-acs-implanted-des